Voyager Therapeutics (NASDAQ:VYGR – Free Report) had its target price reduced by Wedbush from $10.00 to $8.00 in a research note issued to investors on Tuesday morning, Benzinga reports. They currently have a neutral rating on the stock. Wedbush also issued estimates for Voyager Therapeutics’ Q2 2024 earnings at ($0.46) EPS, Q3 2024 earnings at […]

Related Keywords

China , , Citigroup , China Universal Asset Management Co , Alps Advisors Inc , Kestra Advisory Services , Voyager Therapeutics Inc , Voyager Therapeutics , Free Report , Moderate Buy , Therapeutics Trading Down , Get Free Report , Advisory Services , Wealth Management , Universal Asset Management , Aigen Investment Management , Voyager Therapeutics Daily ,